D.A. Davidson & CO. Increases Stock Holdings in TransMedics Group, Inc. (NASDAQ:TMDX)

D.A. Davidson & CO. boosted its position in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 14.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 11,482 shares of the company’s stock after acquiring an additional 1,487 shares during the quarter. D.A. Davidson & CO.’s holdings in TransMedics Group were worth $716,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently bought and sold shares of TMDX. Principal Financial Group Inc. boosted its holdings in TransMedics Group by 260.1% during the 3rd quarter. Principal Financial Group Inc. now owns 202,287 shares of the company’s stock valued at $31,759,000 after acquiring an additional 146,115 shares during the period. Public Sector Pension Investment Board acquired a new stake in TransMedics Group in the 3rd quarter valued at about $11,079,000. Connor Clark & Lunn Investment Management Ltd. raised its position in TransMedics Group by 665.1% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 74,625 shares of the company’s stock valued at $11,716,000 after purchasing an additional 64,872 shares in the last quarter. Vaughan Nelson Investment Management L.P. raised its position in TransMedics Group by 24.3% in the 3rd quarter. Vaughan Nelson Investment Management L.P. now owns 329,010 shares of the company’s stock valued at $51,654,000 after purchasing an additional 64,360 shares in the last quarter. Finally, WCM Investment Management LLC acquired a new stake in TransMedics Group in the 3rd quarter valued at about $8,720,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on TMDX. Piper Sandler reduced their price target on TransMedics Group from $110.00 to $90.00 and set an “overweight” rating on the stock in a research report on Wednesday, December 11th. Oppenheimer reaffirmed an “outperform” rating and issued a $125.00 price target on shares of TransMedics Group in a research report on Tuesday, December 3rd. Robert W. Baird reduced their price target on TransMedics Group from $150.00 to $120.00 and set an “outperform” rating on the stock in a research report on Wednesday, December 11th. Canaccord Genuity Group reduced their price target on TransMedics Group from $109.00 to $104.00 and set a “buy” rating on the stock in a research report on Wednesday, November 20th. Finally, Needham & Company LLC reissued a “hold” rating on shares of TransMedics Group in a research report on Wednesday, February 5th. Three investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $122.70.

Insiders Place Their Bets

In other TransMedics Group news, insider Tamer I. Khayal sold 1,084 shares of TransMedics Group stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $86.40, for a total transaction of $93,657.60. Following the transaction, the insider now owns 20,843 shares of the company’s stock, valued at $1,800,835.20. The trade was a 4.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 7.00% of the stock is currently owned by corporate insiders.

TransMedics Group Trading Up 7.2 %

TMDX opened at $77.12 on Tuesday. The firm has a market cap of $2.59 billion, a price-to-earnings ratio of 82.04 and a beta of 2.12. TransMedics Group, Inc. has a 52 week low of $55.00 and a 52 week high of $177.37. The business’s 50 day moving average is $66.63 and its two-hundred day moving average is $103.87. The company has a quick ratio of 7.33, a current ratio of 8.20 and a debt-to-equity ratio of 2.42.

TransMedics Group Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.